## Abstract The novel vascular targeting agent 5,6‐dimethylxanthenone‐4‐acetic acid (DMXAA) has completed phase 1 clinical trial and has shown tumor antivascular activity in both mice and humans. We have investigated its ability to change tumor vascular permeability, relating it to tumor vascular p
An Improved Synthesis of 5,6-Dimethylxanthenone-4-acetic Acid (DMXAA).
✍ Scribed by Graham J. Atwell; Shangjin Yang; William A. Denny
- Publisher
- John Wiley and Sons
- Year
- 2003
- Weight
- 119 KB
- Volume
- 34
- Category
- Article
- ISSN
- 0931-7597
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
For Abstract see ChemInform Abstract in Full Text.
📜 SIMILAR VOLUMES
## Abstract The effects of two anti‐vascular agents, combretastatin A4 phosphate (CA4P), and 5,6‐dimethylxanthenone‐4‐acetic acid (DMXAA), on the perfusion of two human colon adenocarcinomas implanted in SCID mice, were assessed for up to 3 h using non‐invasive magnetic resonance imaging (MRI) and
## Abstract Uracil‐6‐^14^C (**7**). prepared in high radiochemical yield by conventional methods. has been converted to 5‐fluororacil ‐6‐^14^C (**9**) in over 90% yield using trifluoromethylhypofluorite. The use of this recently introduced reagent eliminates the necessity of preparing **9** from fl
## Abstract For Abstract see ChemInform Abstract in Full Text.